Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes

European Journal of Cancer

Volumn 48, Issue 13, 2012, Pages 2066-2074

  Liedtke, Cornelia ^a   Packeisen, Jens ^b   Hess, Kenneth R ^c   Vogt, Ulf ^d   Kiesel, Ludwig ^a   Kersting, Christian ^e   Korsching, Eberhardt ^f   Brandt, Burkhard ^g   Buerger, Horst ^e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Institute of Pathology   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d European Center of Molecular Cancer Research   (Germany)

^e Institute of Pathology   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Breast cancer; Chemotherapy sensitivity and resistance assays (CSRA's); Molecular subtypes; Tissue mircroarray (TMA)

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 19; CYTOKERATIN 5; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; TUMOR MARKER; VIMENTIN;

ANTIGEN EXPRESSION; ARTICLE; ASSAY; BASAL LIKE BREAST CANCER; BIOLUMINESCENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHEMOTHERAPY SENSITIVITY AND RESISTANCE ASSAY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; PHENOTYPE; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865136885     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.08.006     Document Type: Article

References (39)

1. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 2009 1319 1329
2. L.J. van 't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 2002 530 536 (Pubitemid 34130608)
3. L. Pusztai Lost in translation-prognostic signatures for breast cancer Nat Clin Pract Oncol 5 7 2008 363 (Pubitemid 351958957)
4. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
5. A. Prat, and C.M. Perou Deconstructing the molecular portraits of breast cancer Mol Oncol 5 1 2011 5 23
6. A. Prat, J.S. Parker, and O. Karginova Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res 12 5 2010 R68
7. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 2001 10869 10874 (Pubitemid 32878711)
8. R. Rouzier, C.M. Perou, and W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 2005 5678 5685 (Pubitemid 41170290)
9. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 2008 1275 1281
10. L.A. Carey, E.C. Dees, and L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2007 2329 2334 (Pubitemid 46698581)
11. C.M. Kurbacher, and I.A. Cree Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements Methods Mol Med 110 2005 101 120
12. P.E. Andreotti, I.A. Cree, and C.M. Kurbacher Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma Cancer Res 55 22 1995 5276 5282
13. U. Vogt, B. Falkiewicz, K. Bielawski, U. Bosse, and C. Schlotter Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay Acta Biochim Pol 47 1 2000 157 164
14. J. Kononen, L. Bubendorf, and A. Kallioniemi Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 7 1998 844 847 (Pubitemid 28331029)
15. E. Korsching, J. Packeisen, and K. Agelopoulos Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis Lab Invest 82 11 2002 1525 1533 (Pubitemid 35332911)
16. E. Korsching, J. Packeisen, W. Bocker, and H. Burger Bootstrapping algorithm approach reveals inherent regulatory pattern in 550 invasive breast cancer cases: CK5/6/CK14 and CK8/18/CK19 builds an antagonistic set Verh Dtsch Ges Pathol 89 2005 207 210
17. E. Korsching, J. Packeisen, and C. Liedtke The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206 4 2005 451 457 (Pubitemid 41025348)
18. O. Gluz, C. Liedtke, and N. Gottschalk Triple-negative breast cancer-current status and future directions Ann Oncol 20 12 2009 1913 1927
19. E.A. Rakha, and I.O. Ellis Triple-negative/basal-like breast cancer: review Pathology 41 1 2009 40 47
20. E. Lerma, G. Peiro, and T. Ramon Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) Mod Pathol 20 11 2007 1200 1207 (Pubitemid 47609069)
21. D.J. Dabbs, M. Chivukula, G. Carter, and R. Bhargava Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile Mod Pathol 19 11 2006 1506 1511 (Pubitemid 44624171)
22. E. Korsching, S.S. Jeffrey, and W. Meinerz Basal carcinoma of the breast revisited: an old entity with new interpretations J Clin Pathol 61 5 2008 553 560 (Pubitemid 351678206)
23. T.O. Nielsen, F.D. Hsu, and K. Jensen Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 2004 5367 5374 (Pubitemid 39100473)
24. B.A. Gusterson, D.T. Ross, V.J. Heath, and T. Stein Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer Breast Cancer Res 7 4 2005 143 148 (Pubitemid 40872776)
25. M. Fernandez-Sanchez, A. Gamboa-Dominguez, and N. Uribe Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer Med Oncol 23 2 2006 171 183 (Pubitemid 43780300)
26. R. Rouzier, L. Pusztai, and S. Delaloge Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 23 33 2005 8331 8339
27. T. Petit, M. Wilt, and M. Velten Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 2 2004 205 211 (Pubitemid 38077022)
28. J. Sjostrom, C. Blomqvist, and P. Heikkila Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin Cancer Res 6 8 2000 3103 3110 (Pubitemid 30637734)
29. M. Colozza, A. Sidoni, and M. Piccart-Gebhart Value of Ki67 in breast cancer: the debate is still open Lancet Oncol 11 5 2010 414 415
30. E. de Azambuja, F. Cardoso, and G. de Castro Jr. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients Br J Cancer 96 10 2007 1504 1513 (Pubitemid 46762956)
31. C. Liedtke, C. Hatzis, and W.F. Symmans Genomic grade index is associated with response to chemotherapy in patients with breast cancer J Clin Oncol 27 19 2009 3185 3191
32. J.A. Sparano, M. Wang, and S. Martino Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 16 2008 1663 1671 (Pubitemid 351549913)
33. J. Sargent, A. Elgie, and C.G. Taylor The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay Contrib Gynecol Obstet 19 1994 64 75
34. A.P. Wilson, C.H. Ford, C.E. Newman, and A. Howell A comparison of three assays used for the in vitro chemosensitivity testing of human tumours Br J Cancer 49 1 1984 57 63 (Pubitemid 14194027)
35. J.K. Wilson, J.M. Sargent, A.W. Elgie, J.G. Hill, and C.G. Taylor A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy Br J Cancer 62 2 1990 189 194 (Pubitemid 20242433)
36. G.I. Lau, W.T. Loo, and L.W. Chow Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity assay achieves better tumor response Biomed Pharmacother 61 9 2007 562 565 (Pubitemid 47562693)
37. I.A. Cree, C.M. Kurbacher, A. Lamont, A.C. Hindley, and S. Love A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer Anticancer Drugs 18 9 2007 1093 1101 (Pubitemid 47294903)
38. I.A. Cree, and C.M. Kurbacher Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs 8 6 1997 541 548 (Pubitemid 27373433)
39. Y. Maehara, H. Anai, R. Tamada, and K. Sugimachi The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability Eur J Cancer Clin Oncol 23 3 1987 273 276 (Pubitemid 17033675)